Lab
Medical Diagnostic Laboratories,llc
Medical Diagnostic Laboratories,llc was paid $80.98M by Medicaid between Jan 2018 and Dec 2024, across 91 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 24% of everything it billed.
33Billing provider infoMEDICAL DIAGNOSTIC LABORATORIES,LLC
HAMILTON, NJ 08690
HAMILTON, NJ 08690
33aNPI1750373908assigned 08/15/2005
33bProvider typeClinical Medical Laboratory
28Total paid$80.98M
24GClaims4,890,327
24DCodes billed91
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in New Jersey
Rank by total paid#7 of 122
Median peer was paid$1.29M
This provider vs. median63×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 646,119 | $12.72M | |
| 2019 | 648,371 | $11.71M | |
| 2020 | 623,879 | $12.05M | |
| 2021 | 801,089 | $12.26M | |
| 2022 | 763,859 | $10.65M | |
| 2023 | 751,113 | $11.21M | |
| 2024incomplete | 655,897 | $10.37M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 24% | 1,144,638 | 349,982 | $19.34M |
| 87481 | 16% | 811,501 | 279,933 | $12.71M | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 12% | 509,073 | 471,776 | $9.93M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 9.5% | 502,571 | 465,210 | $7.66M |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 8.2% | 453,787 | 420,770 | $6.66M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 6.5% | 79,671 | 49,833 | $5.29M |
| 87511 | 5.2% | 289,134 | 266,841 | $4.20M | |
| 87653 | 3.6% | 198,937 | 182,489 | $2.88M | |
| 87563 | 2.4% | 169,572 | 153,981 | $1.97M | |
| 87529 | 2.1% | 96,604 | 51,954 | $1.71M | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 2.1% | 107,917 | 100,862 | $1.71M |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 2.1% | 142,754 | 134,622 | $1.71M |
79 more codes
| 87640 | 1.4% | 85,772 | $1.13M | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 10,132 | $504K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 30,860 | $351K |
| 81162 | <1% | 273 | $319K | |
| 88141 | <1% | 23,145 | $200K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,149 | $185K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 9,522 | $173K |
| 81226 | <1% | 3,073 | $144K | |
| 87900 | <1% | 3,149 | $134K | |
| 88341 | <1% | 4,355 | $128K | |
| 87625 | <1% | 6,762 | $122K | |
| 88342 | <1% | 4,475 | $119K | |
| 86617 | <1% | 6,912 | $114K | |
| 81514 | <1% | 1,814 | $103K | |
| 87641 | <1% | 5,422 | $82K | |
| 86618 | <1% | 7,833 | $80K | |
| 81401 | <1% | 5,296 | $79K | |
| 81225 | <1% | 2,997 | $78K | |
| 87799 | <1% | 32,535 | $74K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 1,090 | $67K |
| 87512 | <1% | 6,439 | $63K | |
| 81211 | <1% | 53 | $63K | |
| 87493 | <1% | 3,890 | $52K | |
| 86753 | <1% | 3,798 | $47K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,648 | $47K |
| 86665 | <1% | 2,475 | $47K | |
| 81227 | <1% | 2,643 | $41K | |
| 86611 | <1% | 5,250 | $40K | |
| 81350 | <1% | 2,058 | $38K | |
| 86666 | <1% | 3,510 | $36K | |
| 86663 | <1% | 2,321 | $33K | |
| 86664 | <1% | 2,057 | $30K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 4,282 | $29K |
| 81402 | <1% | 2,806 | $29K | |
| 87999 | <1% | 290 | $29K | |
| 81479 | Unlisted molecular pathology procedure | <1% | 22,813 | $27K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,297 | $27K |
| 86738 | <1% | 2,032 | $23K | |
| 86619 | <1% | 2,419 | $22K | |
| 87184 | <1% | 3,827 | $19K | |
| 86790 | <1% | 2,051 | $19K | |
| 87106 | <1% | 5,446 | $18K | |
| 87186 | <1% | 5,729 | $18K | |
| 87476 | <1% | 1,224 | $18K | |
| 87102 | <1% | 5,748 | $18K | |
| 86645 | <1% | 2,068 | $17K | |
| 81291 | <1% | 2,614 | $17K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 7,519 | $16K |
| 87581 | <1% | 1,329 | $15K | |
| 86644 | <1% | 2,052 | $15K | |
| 81408 | <1% | 52 | $14K | |
| G0124 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | <1% | 1,880 | $10K |
| 87070 | <1% | 3,191 | $10K | |
| 87486 | <1% | 875 | $10K | |
| 87498 | <1% | 849 | $9K | |
| 87623 | <1% | 5,307 | $8K | |
| 88312 | <1% | 369 | $6K | |
| 87532 | <1% | 288 | $6K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,785 | $5K |
| 81321 | <1% | 29 | $5K | |
| 81405 | <1% | 57 | $4K | |
| 87634 | <1% | 530 | $4K | |
| 86632 | <1% | 568 | $3K | |
| 86788 | <1% | 319 | $2K | |
| 81406 | <1% | 29 | $2K | |
| 81307 | <1% | 28 | $2K | |
| 86631 | <1% | 566 | $2K | |
| 86789 | <1% | 321 | $2K | |
| 87496 | <1% | 108 | $2K | |
| 81400 | <1% | 103 | $1K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 166 | $1K |
| 86696 | <1% | 124 | $984.73 | |
| 88304 | <1% | 125 | $876.13 | |
| 86695 | <1% | 136 | $695.74 | |
| 81213 | <1% | 17 | $605.85 | |
| 81255 | <1% | 49 | $414.20 | |
| 81243 | <1% | 18 | $119.79 | |
| 86793 | <1% | 13 | $99.45 | |
| 81164 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORDECHAI, ELI (CHIEF EXECUTIVE OFFICER)